Atypical Ductal Hyperplasia (ADH) is a disease of the proliferative breast lesion characterized with atypia and when diagnosed on core needle biopsy (CNB), excisional biopsy is the current management to exclude adjacent cancer, which may found 10 to 20%.
OBJECTIVE:
The purpose of the study is to investigate the role of biomarkers on surgical decision after the diagnosis of ADH on CNB.
METHODS:
Patients with pure ADH on core biopsy were retrospectively selected, and categorized according to final pathology after excision into three groups: Group I (n: 39) ADH; Group II (n: 27) ductal carcinoma in situ(DCIS), and Group III (n: 9) invasive cancer (IC). Immunohistochemical analyses were performed using biomarkers MUC1, Ki67, Cyclin B1, and Cyclin D1.
RESULTS:
Only Cyclin D1 was significant in between group analysis by one-way ANOVA (64.74, 49.44, and 51.11, respectively; p= 0.01). However when appropriate cut-off levels (2%-50%) were used for each biomarkers using X2 test, no statistical significance was found.
CONCLUSION:
MUC1, Ki67, Cyclin B, and Cyclin D1have failed to predict adjacent cancer on core biopsy specimens with ADH. Further surgery is warranted for all ADH cases diagnosed on core biopsies until a new predictor is identified.
PinderSE, EllisIO, The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)-current definitions and classification, Breast Cancer Res5 (2003), 254-257.
2.
DupontWD, ParlFF, HartmannWH, BrintonLA, WinfieldAC, WorrellJA, et al., Breast cancer risk associated with proliferative breast disease and atypical hyperplasia, Cancer71 (1993), 1258-1265.
3.
PageDL, DupontWD, RogersLW, LandenbergerM, Intraductal carcinoma of the breast: follow-up after biopsy only, Cancer49 (1982), 751-758.
4.
PolatAK, Kanbour-ShakirA, AndacogluO, PolatAV, JohnsonR, BonaventuraM, et al., Atypical Hyperplasia on Core Biopsy: Is Further Surgery Needed?Am J Med Sci344 (2012), 28-3.
5.
DarlingML, SmithDN, LesterSC, KaelinC, SellandDL, DenisonCM, et al., Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: results of surgical excision, Am J Roentgenol175 (2000), 1341-1346.
6.
DegnimAC, KingTA, Surgical management of high-risk breast lesions, Surg Clin North Am93 (2013), 329-40.
7.
GamLH, Breast cancer and protein biomarkers, World J Exp Med20 (2012), 86-89.
8.
RosenPP, Ductal hyperplasia, In: Rosen's Breast Pathology, 2nd ed. Philadelphia, PA: Lippincott Williams &Wilkins, 2001, pp. 201-228.
9.
SchnittSJ, Vincent-SalomonA, Columnar cell lesions of the breast, Adv Anat Pathol10 (2003), 113-124.
10.
American College of Radiology. Breast Imaging Reporting and Data System Atlas. 2003. Available at: http://www. acr.org/departments/stand_accred/birads/ contents.html. Accessed August 19, 2004.
11.
RassidakisGZ, GoyA, MedeirosLJ, JiangY, ThomaidesA, RemacheY, CabanillasF, et al., Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma, Clin Cancer Res9 (2003), 2213-2220.
12.
AndacogluO, Kanbour-ShakirA, TehYC, BonaventuraM, OzbekU, AnelloM, et al., Rationale of Excisional Biopsy After the Diagnosis of Benign Radial Scar on Core Biopsy: A Single Institutional Outcome Analysis, Am J Clin Oncol36 (2013), 7-11.
13.
KrishnamurthyS, BeversT, KuererH, YangWT, Multidisciplinary considerations in the management of high-risk breast lesions, AJR Am J Roentgenol198 (2012), 132-140.
14.
EbyPR, OchsnerJE, DeMartiniWB, AllisonKH, PeacockS, LehmanCD, Frequency and upgrade rates of atypical ductal hyperplasia diagnosed at stereotactic vacuum-assisted breast biopsy: 9-versus 11-gauge, AJR Am J Roentgenol192 (2009), 229-234.
15.
HoussamiN, CiattoS, EllisI, AmbrogettiD, Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates, Cancer109 (2007), 487-495.
16.
ForgeardC, BenchaibM, GuerinN, ThiesseP, MignotteH, FaureC, et al., Is surgical biopsy mandatory in case of atypical ductal hyperplasia on 11-gauge core needle biopsy? A retrospective study of 300 patients, Am J Surg196 (2008), 339-345.
17.
KhouryT, ChenX, WangD, KumarP, QinM, LiuS, et al., Nomogram to predict the likelihood of upgrade of atypical ductal hyperplasia diagnosed on a core needle biopsy in mammographically detected lesions, Histopathology67 (2015), 106-20.
18.
NguyenCV, AlbarracinCT, WhitmanGJ, LopezA, SneigeN, Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: Considerations for surgical excision, Ann Surg Oncol18 (2011), 752-761.
19.
DeshaiesI, ProvencherL, JacobS, CôtéG, RobertJ, DesbiensC, et al., Factors associated with upgrading to malignancy at surgery of atypical ductal hyperplasia diagnosed on core biopsy, Breast20 (2011), 50-55.
20.
ViacavaP, NaccaratoAG, BevilacquaG, Different proliferative patterns characterize different preinvasive breast lesions, J Pathol188 (1999), 245-251.
21.
XuR, PerleMA, InghiramiG, ChanW, DelgadoY, FeinerH, Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material, Mod Pathol15 (2002), 116-124.
22.
LacunzaE, BaudisM, ColussiAG, Segal-EirasA, CroceMV, AbbaMC, MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells, Cancer Genet Cytogenet201 (2010), 102-110.
23.
LiuT, NiuY, FengY, NiuR, YuY, LvA, et al., Methylation of CpG islands of p16 (INK4a) and cyclinD1 overexpression associated with progression of intraductal proliferative lesions of the breast, Hum Pathol39 (2008), 1637-46.
24.
RadiskyDC, SantistebanM, BermanHK, GauthierML, FrostMH, ReynoldsCA, et al., p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res (Phila)4 (2011), 1953-1960.
25.
FacklerMJ, RiversA, TeoWW, MangatA, TaylorE, ZhangZ, et al., Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge, Clin Cancer Res15 (2009), 3802-3811.
26.
UmbrichtCB, EvronE, GabrielsonE, FergusonA, MarksJ, SukumarS, Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer, Oncogene20 (2001), 3348-3353.
27.
ZagouriF, SergentanisTN, NonniA, PapadimitriouCA, MichalopoulosNV, DomeyerP, et al., Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions, BMC Cancer10 (2010), 353.
28.
PolyakK, Is breast tumor progression really linear?Clin Cancer Res15 (2008), 339-341.
29.
ChaiH, BrownRE, Field effect in cancer-an update, Ann Clin Lab Sci39 (2009), 331-337.
30.
LarsonPS, de las MorenasA, CupplesLA, HuangK, RosenbergCL, Genetically abnormal clones in histologically normal breast tissue, Am J Pathol152 (1998), 1591-1598.
31.
KanekoM, ArihiroK, TakeshimaY, FujiiS, InaiK, Loss of heterozygosity and microsatellite instability in epithelial hyperplasia of the breast, J Exp Ther Oncol2 (2002), 9-18.
